Frye, Björn Christian
Potasso, Laura
Farin-Glattacker, Erik
Birring, Surrinder
Müller-Quernheim, Joachim
Schupp, Jonas Christian
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Received: 17 June 2021
Accepted: 17 November 2021
First Online: 3 December 2021
Declarations
:
: The study was approved by the local Ethics Committee of the University of Freiburg and data collection and handling followed the rules of “Good clinical Practice” according to the declaration of Helsinki and regulations concerning data handling.
: All patients gave informed consent to participation at this study and to data handling and data analysis including publication. All authors approved the final version of the manuscript and agreed to publishing.
: BCF indicates personal fees (speaking and consulting fees) within the last three years from Actelion, AdVita, Astra Zeneca, Boehringer Ingelheim, Novartis and Roche. BCF is co-founder of Advita Lifescience GmbH. LP has nothing to disclose. EF has nothing to disclose.SB indicates fees to King’s Colleges Hospital from Atyr and Actelion for use of KS . JMQ has nothing to disclose. JCS has nothing to disclose.